EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Value of pepsinogen I in serum as a screening method for early detection of gastroduodenal lesions and follow-up in therapy with non-steroidal antirheumatic drugs



Value of pepsinogen I in serum as a screening method for early detection of gastroduodenal lesions and follow-up in therapy with non-steroidal antirheumatic drugs



Zeitschrift für Rheumatologie 50(1): 39-45



Gastroduodenal lesions of the mucosa are known to be the most frequent side effect during therapy with non-steroidal antiinflammatory drugs (NSAIDs). We investigated the radioimmunological determination of serum-pepsinogen I as an indicator for the quality of the gastroduodenal mucosa. A good correlation was found between the endoscopy findings of 78 patients and contemporary determinations of serum-pepsinogen. Further, a follow-up of pepsinogen I was made during the treatment of 107 patients with degenerative rheumatic diseases with eight different NSAIDs. The results recommend the determination of pepsinogen I as an indicator of gastroduodenal mucosal changes under therapy with NSAIDs; this determination gives a deciding factor for the gastrolesive potency of an NSAID.

(PDF emailed within 1 workday: $29.90)

Accession: 041937348

Download citation: RISBibTeXText

PMID: 2058321



Related references

Value of determining pepsinogen i in serum as a screening method for the early detection of gastroduodenal lesions and as a way to manage treatment with nonsteroidal antirheumatic drugs. Zeitschrift fuer Rheumatologie 50(1): 39-45, 1991

Current state of treatment and prevention of gastroduodenal side effects of non-steroidal antirheumatic drugs. Leber, Magen, Darm 21(5): 193-4, 196, 1991

Five years follow-up of participants in stomach cancer screening by serum pepsinogen test method. American Journal of Gastroenterology 98(9 Supplement): S44, September, 2003

Segmental small intestine lesions after taking non-steroidal antirheumatic drugs. Deutsche Medizinische Wochenschrift 120(13): 436-441, 1995

Gastroduodenal lesions induced by non-steroidal antiinflammatory drugs. Klinicheskaia Meditsina 75(3): 69-71, 1997

Risk of ulcer and its prophylaxis in therapy with non-steroidal antirheumatic drugs. Medizinische Klinik 92(12): 726-735, 1998

Two cases of early colorectal cancer associated with gastric adenoma detected by serum pepsinogen screening method. Advances in Experimental Medicine and Biology 362: 149-154, 1995

Therapy of non-steroidal antirheumatic drug-induced gastrointestinal lesions with misoprostol. Zeitschrift für Rheumatologie 50(3): 175-180, 1991

Gastroduodenal erosive and ulcerous lesions induced by non-steroidal antiinflammatory drugs. Klinicheskaia Meditsina 86(2): 8-14, 2008

Pathogenesis of gastroduodenal lesions induced by non-steroidal anti-inflammatory drugs. Gastroenterologie Clinique et Biologique 28 Spec No 3: C18-C26, 2004

Serum pepsinogen levels in different gastroduodenal lesions and in subjects from two areas with contrasting gastric cancer rates. Gastroenterology 112(4 SUPPL ): A599, 1997

Interobserver variation in assessment of gastroduodenal lesions associated with non-steroidal anti-inflammatory drugs. Gut 35(8): 1030-1032, 1994

Gastroduodenal lesions and non-steroidal anti-inflammatory drugs: Which is the role of Helicobacter pylori in this relation?. Revista Espanola de Enfermedades Digestivas 90(9): 655-664, Sept, 1998

Changes in the serum pepsinogen level during therapy with acemtacin retard as a measure of gastroduodenal tolerance. Wiener Medizinische Wochenschrift 141(15): 331-335, 1991

Evaluation of the development of gastroduodenal lesions in patients treated with low-dose aspirin or non-steroidal anti-inflammatory drugs. Yakugaku Zasshi 131(7): 1085-1094, 2012